Sign In / Register
Make This My Home Page | Feedback |RSS
Search
You are here: IE »   Story

Sun Pharma replaces Satyam in Sensex

  • Print
  • Mail This Article
  • Comments
  • BSE

    The Bombay Stock Exchange on Thursday said it will replace Satyam Computer with Sun Pharmaceutical in its benchmark index Sensex with effect from January 12.

    Satyam would also be removed from various other indices like BSE-100, BSE 200, BSE-500 and BSE Teck and BSE IT index, the exchange said in a statement.

    "Trading members of the exchange are hereby informed that the replacements would be made with effect from January 12, 2009," the statement added.

    Further, GlaxoSmithkline Pharmaceuticals would replace Satyam in the BSE 100 index, while the IT firm would be replaced by Castrol India in the BSE 200 index.

    Meanwhile, Cadila Healthcare replaces Satyam Computer in the BSE-500 index.

    The statement by the exchange comes a day after the NSE said it would strike off Satyam from its benchmark index Nifty with effect from January 12.

    The National Stock Exchange has removed the company from various other indices like the CNX 100, S&P CNX 500, CNX IT and the CNX Services sector index.

    Express Specials
    Comments
    Post comment

    Be the first to comment.

    Post a Comment
    Name:
    Email:
    Title:
    Maximum characters allowed     
    Comment:
    TERMS OF USE:
    The views, opinions and comments posted are your, and are not endorsed by this website. You shall be solely responsible for the comment posted here. The website reserves the right to delete, reject, or otherwise remove any views, opinions and comments posted or part thereof. You shall ensure that the comment is not inflammatory, abusive, derogatory, defamatory &/or obscene, or contain pornographic matter and/or does not constitute hate mail, or violate privacy of any person (s) or breach confidentiality or otherwise is illegal, immoral or contrary to public policy. Nor should it contain anything infringing copyright &/or intellectual property rights of any person(s).
    I agree to the terms of use.